Jesse D. Sammon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jesse D. Sammon has a total of 169 co-authors. Here are the top co-authors by number of shared publications:
Mani Menon
Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan
18 shared publicationsQuoc-Dien Trinh
Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
12 shared publications- Akshay Sood
Department of Urology, The James Cancer Hospital and Solove Research Institute, The Ohio State University Wexner Medical Center, Columbus, Ohio
11 shared publications - Firas Abdollah
Vattikuti Urology Institute, Henry Ford Health System, Detroit, USA
11 shared publications Shyam Sukumar
Center for Outcomes Research and Analytics, Henry Ford Health System, Detroit, MI; Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI
11 shared publications- Quoc-Dien Trinh
Department of Urology, University of Pittsburgh, Pittsburgh, PA
9 shared publications
Latest Publications
- Open Access
PRState: Incorporating Genetic Ancestry in Prostate Cancer Risk scores for African American Men
Prostate cancer (PrCa) is one of the most genetically driven solid cancers with heritability estimates as high as 57%. African American men are at an increased risk of PrCa; however, current risk prediction models are based on European ancestry groups and may not be broadly applicable. In this study, we define an African ancestry group of 4,533 individuals to develop an African ancestry-specific PrCa polygenic risk score (PRState). We identified risk loci on chromosomes 3, 8, and 11 in the African ancestry group GWAS and constructed a polygenic risk score (PRS) from 10 African ancestry-specific PrCa risk SNPs, achieving an AUC of 0.61 [0.60-0.63] and 0.65 [0.64-0.67], when combined with age and family history. Performance dropped significantly when using ancestry-mismatched PRS models but remained comparable when using trans-ancestry models. Importantly, we validated the PRState score in the Million Veteran Program, demonstrating improved prediction of PrCa and metastatic PrCa in African American individuals. This study underscores the need for inclusion of individuals of African ancestry in gene variant discovery to optimize PRS.
Open AccessPRState: Incorporating Genetic Ancestry in Prostate Cancer Risk scores for African American Men
Prostate cancer (PrCa) is one of the most genetically driven solid cancers with heritability estimates as high as 57%. African American men are at an increased risk of PrCa; however, current risk prediction models are based on European ancestry groups and may not be broadly applicable. In this study, we define an African ancestry group of 4,533 individuals to develop an African ancestry-specific PrCa polygenic risk score (PRState). We identified risk loci on chromosomes 3, 8, and 11 in the African ancestry group GWAS and constructed a polygenic risk score (PRS) from 10 African ancestry-specific PrCa risk SNPs, achieving an AUC of 0.61 [0.60-0.63] and 0.65 [0.64-0.67], when combined with age and family history. Performance dropped significantly when using ancestry-mismatched PRS models but remained comparable when using trans-ancestry models. Importantly, we validated the PRState score in the Million Veteran Program, demonstrating improved prediction of PrCa and metastatic PrCa in African American individuals. This study underscores the need for inclusion of individuals of African ancestry in gene variant discovery to optimize PRS.
- 1 June 2021
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 205 (6) , 1641-1647
National Recommendations against Prostate Specific Antigen Screening versus Statewide Medicaid Expansion Initiatives: A Battle of the Titans
Purpose:Medicaid expansion under the Affordable Care Act (ACA) occurred almost concurrently with 2012 USPSTF recommendations against PSA screening. Here the relative influence on PSA screening rate...
- 1 June 2021
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 205 (6) , 1641-1647
National Recommendations against Prostate Specific Antigen Screening versus Statewide Medicaid Expansion Initiatives: A Battle of the Titans
Purpose:Medicaid expansion under the Affordable Care Act (ACA) occurred almost concurrently with 2012 USPSTF recommendations against PSA screening. Here the relative influence on PSA screening rate...
- 1 March 2021
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 39 (3) , 192.e15-192.e20
Meditative and mind-body practice among patients with genitourinary malignancy
- 1 March 2021
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 39 (3) , 192.e15-192.e20
Meditative and mind-body practice among patients with genitourinary malignancy
Impact of health literacy on shared decision making for prostate‐specific antigen screening in the United States
Background: Current guidelines endorse shared decision making (SDM) for prostate‐specific antigen (PSA) screening. The relationship between a patient's health literacy (HL) and SDM remains unclear. In the current study, the authors sought to identify the impact of HL on the rates of PSA screening and on the relationship between HL and SDM following the 2012 US Preventive Services Task Force recommendations against PSA screening.Methods: Using data from the 2016 Behavioral Risk Factor Surveillance System, the authors examined PSA screening in the 13 states that administered the optional “Health Literacy” module. Men aged ≥50 years were examined. Complex samples multivariable logistic regression models were computed to assess the odds of undergoing PSA screening. The interactions between HL and SDM were also examined.Results: A weighted sample of 12.249 million men with a rate of PSA screening of 33.4% were identified. Approximately one‐third self‐identified as having optimal HL. Rates of PSA screening were found to be highest amongst the highest HL group (42.2%). Being in this group was a significant predictor of undergoing PSA screening (odds ratio, 1.214; 95% confidence interval, 1.051‐1.403). There was a significant interaction observed between HL and SDM (P for interaction, <.001) such that higher HL was associated with a lower likelihood of undergoing PSA screening when SDM was present.Conclusions: In the uncertain environment of multiple contradictory screening guidelines, men who reported higher levels of HL were found to have higher levels of screening. The authors demonstrated that increased HL may reduce the screening‐promoting effect of SDM. These findings highlight the dynamic interplay between HL and SDM that should inform the creation and promulgation of SDM guidelines, specifically when considering patients with low HL.
Impact of health literacy on shared decision making for prostate‐specific antigen screening in the United States
Background: Current guidelines endorse shared decision making (SDM) for prostate‐specific antigen (PSA) screening. The relationship between a patient's health literacy (HL) and SDM remains unclear. In the current study, the authors sought to identify the impact of HL on the rates of PSA screening and on the relationship between HL and SDM following the 2012 US Preventive Services Task Force recommendations against PSA screening.Methods: Using data from the 2016 Behavioral Risk Factor Surveillance System, the authors examined PSA screening in the 13 states that administered the optional “Health Literacy” module. Men aged ≥50 years were examined. Complex samples multivariable logistic regression models were computed to assess the odds of undergoing PSA screening. The interactions between HL and SDM were also examined.Results: A weighted sample of 12.249 million men with a rate of PSA screening of 33.4% were identified. Approximately one‐third self‐identified as having optimal HL. Rates of PSA screening were found to be highest amongst the highest HL group (42.2%). Being in this group was a significant predictor of undergoing PSA screening (odds ratio, 1.214; 95% confidence interval, 1.051‐1.403). There was a significant interaction observed between HL and SDM (P for interaction, <.001) such that higher HL was associated with a lower likelihood of undergoing PSA screening when SDM was present.Conclusions: In the uncertain environment of multiple contradictory screening guidelines, men who reported higher levels of HL were found to have higher levels of screening. The authors demonstrated that increased HL may reduce the screening‐promoting effect of SDM. These findings highlight the dynamic interplay between HL and SDM that should inform the creation and promulgation of SDM guidelines, specifically when considering patients with low HL.
- 1 September 2020
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 204 (3) , 564-569
Receipt of Survivorship Care Plans and Self-Reported Health Status among Patients with Genitourinary Malignancy
Purpose:Implementation of Survivorship Care Plans (SCP) has been emphasized as a key component to improving care for cancer survivors. Our objective was to determine the prevalence of SCP receipt f...
- 1 September 2020
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 204 (3) , 564-569
Receipt of Survivorship Care Plans and Self-Reported Health Status among Patients with Genitourinary Malignancy
Purpose:Implementation of Survivorship Care Plans (SCP) has been emphasized as a key component to improving care for cancer survivors. Our objective was to determine the prevalence of SCP receipt f...
- 1 December 2018
- Published by Elsevier in European Urology Focus
- Vol. 4 (6) , 775-789
Systematic Review of the Volume–Outcome Relationship for Radical Prostatectomy
- 1 December 2018
- Published by Elsevier in European Urology Focus
- Vol. 4 (6) , 775-789
Systematic Review of the Volume–Outcome Relationship for Radical Prostatectomy
- 27 August 2018
- Published by Springer Nature in World Journal of Urology
- Vol. 37 (6) , 1095-1101
Prostate cancer navigation: initial experience and association with time to care
To evaluate factors associated with use of patient navigation in a prostate cancer population and identify whether navigation is associated with prolonged time to care. Cancer patient navigation has been shown to improve access to cancer screening, diagnosis, and treatment, but little is known about patient navigation in prostate cancer care.
- 27 August 2018
- Published by Springer Nature in World Journal of Urology
- Vol. 37 (6) , 1095-1101
Prostate cancer navigation: initial experience and association with time to care
To evaluate factors associated with use of patient navigation in a prostate cancer population and identify whether navigation is associated with prolonged time to care. Cancer patient navigation has been shown to improve access to cancer screening, diagnosis, and treatment, but little is known about patient navigation in prostate cancer care.
- 1 December 2017
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 198 (6) , 1295-1300
The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE® Military Database
Fee for service reimbursement incentives may affect care. We compared the odds of prostate specific antigen screening among former and active duty United States military service members based on receipt of primary care from integrated military health facilities vs community providers reimbursed via fee for service. We retrospectively studied the records of all active duty and retired male service members 40 to 64 years old who were covered by the TRICARE® military health benefit in 2010. Beneficiaries may receive primary care at military run facilities via the direct care system or with private physicians via the purchased care system. We compared rates of prostate specific antigen screening between propensity score weighted cohorts of 219,290 men who received primary care in the direct care system and 177,748 who received it in the purchased care system. The screening rate was 35% in the direct care system vs 26% in the purchased care system. After propensity score weighting the former men were significantly more likely to undergo prostate specific antigen screening than men who received primary care in the purchased care system (adjusted OR 1.76, 95% CI 1.729-1.781). Age older than 52 years, rank and black race were associated with increased odds of prostate specific antigen screening in each cohort. These results suggest that salaried primary care providers employed at integrated military facilities are more likely to order prostate specific antigen screening compared to those reimbursed in a fee for service fashion by military insurance. Growing understanding of how fee for service incentives impact prostate specific antigen screening by primary care providers may enable advocates and policy makers to leverage reimbursement systems as a tool to change prostate cancer screening.
- 1 December 2017
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 198 (6) , 1295-1300
The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE® Military Database
Fee for service reimbursement incentives may affect care. We compared the odds of prostate specific antigen screening among former and active duty United States military service members based on receipt of primary care from integrated military health facilities vs community providers reimbursed via fee for service. We retrospectively studied the records of all active duty and retired male service members 40 to 64 years old who were covered by the TRICARE® military health benefit in 2010. Beneficiaries may receive primary care at military run facilities via the direct care system or with private physicians via the purchased care system. We compared rates of prostate specific antigen screening between propensity score weighted cohorts of 219,290 men who received primary care in the direct care system and 177,748 who received it in the purchased care system. The screening rate was 35% in the direct care system vs 26% in the purchased care system. After propensity score weighting the former men were significantly more likely to undergo prostate specific antigen screening than men who received primary care in the purchased care system (adjusted OR 1.76, 95% CI 1.729-1.781). Age older than 52 years, rank and black race were associated with increased odds of prostate specific antigen screening in each cohort. These results suggest that salaried primary care providers employed at integrated military facilities are more likely to order prostate specific antigen screening compared to those reimbursed in a fee for service fashion by military insurance. Growing understanding of how fee for service incentives impact prostate specific antigen screening by primary care providers may enable advocates and policy makers to leverage reimbursement systems as a tool to change prostate cancer screening.
- Open Access
Variation in the use of active surveillance for low‐risk prostate cancer
BACKGROUND: This study assessed the use of active surveillance in men with low‐risk prostate cancer and evaluated institutional factors associated with the receipt of active surveillance.METHODS: A retrospective, hospital‐based cohort of 115,208 men with low‐risk prostate cancer diagnosed between 2010 and 2014 was used. Multivariate and mixed effects models were used to examine variation and factors associated with active surveillance.RESULTS: During the study period, the use of active surveillance increased from 6.8% in 2010 to 19.9% in 2014 (estimated annual percentage change, +28.8%; 95% confidence interval [CI], + 19.6% to + 38.7%; P = .002). The adjusted probability of active‐surveillance receipt by institution was highly variable. Compared with patients treated at comprehensive community cancer centers, patients treated at community cancer programs (odds ratio [OR], 2.00; 95% CI, 1.50‐2.67; P < .001) and academic institutions (OR, 2.47; 95%, CI, 1.81‐3.37; P < .001) had higher odds of receiving active surveillance. Compared with patients treated at very low‐volume facilities, patients treated at very high‐volume facilities had higher odds of receiving active surveillance (OR, 3.57; 95% CI, 1.94‐6.55; P < .001). Patient and hospital characteristics accounted for 60.2% of the overall variation, whereas the treating institution accounted for 91.5% of the unexplained variability.CONCLUSIONS: Within this hospital‐based cohort, the use of active surveillance for low‐risk prostate cancer increased significantly over time. Significant variation was found in the use of active surveillance. Most of the variation was attributable to facility‐related factors such as the facility type, facility volume, and institution. Policies to achieve consistent and higher rates of active surveillance, when appropriate, should be a priority of professional societies and patient advocacy groups. Cancer 2018;124:55‐64. © 2017 American Cancer Society.
Open AccessVariation in the use of active surveillance for low‐risk prostate cancer
BACKGROUND: This study assessed the use of active surveillance in men with low‐risk prostate cancer and evaluated institutional factors associated with the receipt of active surveillance.METHODS: A retrospective, hospital‐based cohort of 115,208 men with low‐risk prostate cancer diagnosed between 2010 and 2014 was used. Multivariate and mixed effects models were used to examine variation and factors associated with active surveillance.RESULTS: During the study period, the use of active surveillance increased from 6.8% in 2010 to 19.9% in 2014 (estimated annual percentage change, +28.8%; 95% confidence interval [CI], + 19.6% to + 38.7%; P = .002). The adjusted probability of active‐surveillance receipt by institution was highly variable. Compared with patients treated at comprehensive community cancer centers, patients treated at community cancer programs (odds ratio [OR], 2.00; 95% CI, 1.50‐2.67; P < .001) and academic institutions (OR, 2.47; 95%, CI, 1.81‐3.37; P < .001) had higher odds of receiving active surveillance. Compared with patients treated at very low‐volume facilities, patients treated at very high‐volume facilities had higher odds of receiving active surveillance (OR, 3.57; 95% CI, 1.94‐6.55; P < .001). Patient and hospital characteristics accounted for 60.2% of the overall variation, whereas the treating institution accounted for 91.5% of the unexplained variability.CONCLUSIONS: Within this hospital‐based cohort, the use of active surveillance for low‐risk prostate cancer increased significantly over time. Significant variation was found in the use of active surveillance. Most of the variation was attributable to facility‐related factors such as the facility type, facility volume, and institution. Policies to achieve consistent and higher rates of active surveillance, when appropriate, should be a priority of professional societies and patient advocacy groups. Cancer 2018;124:55‐64. © 2017 American Cancer Society.